DIFFERENCES IN TEMOZOLAMIDE RESPONSE IN GLIOBLASTOMA MULTIFORME: A REPORT OF TWO CASES

Djohan Ardiansyah; Vita Kusuma Rahmawati; Sri Andreani Utomo

doi:10.29342/cnj.v3i3.89

DIFFERENCES IN TEMOZOLAMIDE RESPONSE IN GLIOBLASTOMA MULTIFORME: A REPORT OF TWO CASES

Djohan Ardiansyah, Vita Kusuma Rahmawati, Sri Andreani Utomo

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Glioblastoma multiforme (GBM) accounts for approximately 20% of primary adult-brain neoplasms and has a poor prognosis; life expectancy is 12 months or less after diagnosis. Temozolomide (TMZ) has become the standard therapy for GBM, combined with surgery and radiochemotherapy. Evaluation is important due to its association with the continuity or termination of therapy. Several studies have aimed to improve the measurement of the therapy response of GBM. The Response Assessment in Neuro-Oncology (RANO) criteria, published in 2010, has become a widely used tool for evaluating TMZ response in patients with GBM. These criteria combine clinical manifestation, steroid therapy, and brain magnetic resonance imaging (MRI).

Original language	English
Article number	3
Pages (from-to)	113-121
Number of pages	9
Journal	Callosum Neurology Journal
Volume	3
Issue number	3
DOIs	https://doi.org/10.29342/cnj.v3i3.89
Publication status	Published - 25 Nov 2020

Keywords

glioblastoma multiforme, prognosis, Response Assessment in Neuro-Oncology, temozolomide.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.29342/cnj.v3i3.89

Cite this

@article{bb1fd238b903430794ec55083def4271,

title = "DIFFERENCES IN TEMOZOLAMIDE RESPONSE IN GLIOBLASTOMA MULTIFORME: A REPORT OF TWO CASES",

abstract = "Background: Glioblastoma multiforme (GBM) accounts for approximately 20% of primary adult-brain neoplasms and has a poor prognosis; life expectancy is 12 months or less after diagnosis. Temozolomide (TMZ) has become the standard therapy for GBM, combined with surgery and radiochemotherapy. Evaluation is important due to its association with the continuity or termination of therapy. Several studies have aimed to improve the measurement of the therapy response of GBM. The Response Assessment in Neuro-Oncology (RANO) criteria, published in 2010, has become a widely used tool for evaluating TMZ response in patients with GBM. These criteria combine clinical manifestation, steroid therapy, and brain magnetic resonance imaging (MRI).",

keywords = "glioblastoma multiforme, prognosis, Response Assessment in Neuro-Oncology, temozolomide.",

author = "Djohan Ardiansyah and Rahmawati, {Vita Kusuma} and Utomo, {Sri Andreani}",

year = "2020",

month = nov,

day = "25",

doi = "10.29342/cnj.v3i3.89",

language = "English",

volume = "3",

pages = "113--121",

journal = "Callosum Neurology Journal",

number = "3",

}

TY - JOUR

T1 - DIFFERENCES IN TEMOZOLAMIDE RESPONSE IN GLIOBLASTOMA MULTIFORME: A REPORT OF TWO CASES

AU - Ardiansyah, Djohan

AU - Rahmawati, Vita Kusuma

AU - Utomo, Sri Andreani

PY - 2020/11/25

Y1 - 2020/11/25

N2 - Background: Glioblastoma multiforme (GBM) accounts for approximately 20% of primary adult-brain neoplasms and has a poor prognosis; life expectancy is 12 months or less after diagnosis. Temozolomide (TMZ) has become the standard therapy for GBM, combined with surgery and radiochemotherapy. Evaluation is important due to its association with the continuity or termination of therapy. Several studies have aimed to improve the measurement of the therapy response of GBM. The Response Assessment in Neuro-Oncology (RANO) criteria, published in 2010, has become a widely used tool for evaluating TMZ response in patients with GBM. These criteria combine clinical manifestation, steroid therapy, and brain magnetic resonance imaging (MRI).

AB - Background: Glioblastoma multiforme (GBM) accounts for approximately 20% of primary adult-brain neoplasms and has a poor prognosis; life expectancy is 12 months or less after diagnosis. Temozolomide (TMZ) has become the standard therapy for GBM, combined with surgery and radiochemotherapy. Evaluation is important due to its association with the continuity or termination of therapy. Several studies have aimed to improve the measurement of the therapy response of GBM. The Response Assessment in Neuro-Oncology (RANO) criteria, published in 2010, has become a widely used tool for evaluating TMZ response in patients with GBM. These criteria combine clinical manifestation, steroid therapy, and brain magnetic resonance imaging (MRI).

KW - glioblastoma multiforme, prognosis, Response Assessment in Neuro-Oncology, temozolomide.

U2 - 10.29342/cnj.v3i3.89

DO - 10.29342/cnj.v3i3.89

M3 - Article

VL - 3

SP - 113

EP - 121

JO - Callosum Neurology Journal

JF - Callosum Neurology Journal

IS - 3

M1 - 3

ER -

DIFFERENCES IN TEMOZOLAMIDE RESPONSE IN GLIOBLASTOMA MULTIFORME: A REPORT OF TWO CASES

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this